Study on Adding Venetoclax to Treatment for First-Line Chronic Lymphocytic Leukemia to Achieve Long-Lasting Remissions

Inclusion Criteria

• Diagnosed with chronic lymphocytic leukemia (CLL) and currently on a stable dose of a covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) like ibrutinib, acalabrutinib, or zanubrutinib for at least 6 months as first-line treatment.
• Showing at least a partial response to the current treatment based on specific medical criteria.
• Have a performance status score of 2 or less, indicating the ability to carry out daily activities with some limitations.
• Have adequate kidney and liver function as determined by medical tests.

Exclusion Criteria

• Have previously received B-cell lymphoma (Bcl-2) inhibitor therapy.
• Have disease that is not improving or is stable on the current cBTKi treatment.
• Have CLL that has transformed into a more aggressive form of cancer, such as non-Hodgkin lymphoma or pro-lymphocytic leukemia.
• Have a history of heart muscle disease (cardiomyopathy).
• Have an allergy to venetoclax or any of its ingredients.
• Have significant heart disease.
• Have active bleeding issues or a history of bleeding disorders.
• Are pregnant or breastfeeding.
• Have uncontrolled autoimmune conditions affecting red blood cells or platelets.